AHCL
Anlon Healthcare Limited
Anlon Healthcare Limited (AHCL) financial statements and selected valuation metrics through 30 June 2026.
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
anlon.in(opens the company website in a new tab)Key metrics
Price as of 2026-10-16
Full years shown; sign in free for the trailing twelve months. Learn about these metrics →
Price & valuation
Share price and valuation multiples (P/E, P/B and more) over time.
Loading price history…
Compare with peers
Loading peers…
What you need to know
Anlon Healthcare (AHCL) makes pharmaceutical intermediates and active pharmaceutical ingredients (APIs) for pharmaceutical, nutraceutical, personal care and animal health customers in India and abroad.
Company snapshot
86thBy market cap
Ranked among 119 companies in Pharmaceuticals.
What we see
- ✓Net margin of 16.9% — the business keeps a healthy share of every rupee it earns.
- ✗Operating cash flow is negative even though the company shows a profit — the business may not be generating real cash yet.
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Mar 2026 | Jun 2026 |
|---|---|---|
| Sales | 51 Cr | 88 Cr |
| Operating expenses (approx.) | 36 Cr | 72 Cr |
| EBITDA | 15 Cr | 16 Cr |
| OPM % | 30.0% | 17.8% |
| Other income | 0.01 Cr | 0.06 Cr |
| Interest | 0.57 Cr | 0.92 Cr |
| Depreciation | 0.29 Cr | 1 Cr |
| Profit before tax | 14 Cr | 14 Cr |
| Tax % | 23.3% | 39.4% |
| Net profit | 11 Cr | 8 Cr |
| EPS (₹) | ₹2.33 | ₹0.16 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2026 | TTM |
|---|---|---|
| Sales | 172 Cr | Sign in free for the trailing twelve months |
| Operating expenses (approx.) | 124 Cr | Sign in free for the trailing twelve months |
| EBITDA | 48 Cr | Sign in free for the trailing twelve months |
| OPM % | 27.6% | Sign in free for the trailing twelve months |
| Other income | 0.26 Cr | Sign in free for the trailing twelve months |
| Interest | 4 Cr | Sign in free for the trailing twelve months |
| Depreciation | 2 Cr | Sign in free for the trailing twelve months |
| Profit before tax | 43 Cr | Sign in free for the trailing twelve months |
| Tax % | 31.6% | Sign in free for the trailing twelve months |
| Net profit | 29 Cr | Sign in free for the trailing twelve months |
| EPS (₹) | ₹6.11 | Sign in free for the trailing twelve months |
| Dividend payout % | 0.0% | Sign in free for the trailing twelve months |
The latest four quarters added up, next to each full year
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2026 |
|---|---|
| Equity capital | 53 Cr |
| Reserves | 177 Cr |
| Borrowings | 44 Cr |
| Other liabilities | 76 Cr |
| Total liabilities | 374 Cr |
| Fixed assets (net) | 58 Cr |
| CWIP | — |
| Investments | 0.99 Cr |
| Loans & advances | 0.19 Cr |
| Inventories | 113 Cr |
| Trade receivables | 104 Cr |
| Cash & bank | 4 Cr |
| Other assets | 94 Cr |
| Total assets | 374 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2026 |
|---|---|
| Cash from operating activity | -79 Cr |
| Cash from investing | -36 Cr |
| Cash from financing | 119 Cr |
| Net cash flow | 3 Cr |
| Free cash flow (OCF − Capex) | -79 Cr |
Ratios
| Metric | Mar 2026 |
|---|---|
| ROCE % | 15.5% |
| ROE % | 11.2% |
| Debtor days | 219 |
| Inventory days | 276 |
| Days payable | 103 |
| Cash conversion cycle | 392 |
| OCF / EBITDA % | -167.2% |
| Debt / equity | 0.19 |
| Current ratio | 2.87 |
| Net debt / EBITDA | 0.83 |